Weight-loss drug startup Metsera wants to take on Novo and Lilly. Here's what you need to know
by Fast Company
Fast Company— Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss treatments that it hopes to bring to market. The company, which has already acquired the U.K.-based startup, Zihipp, and formed a licensing pact with a South Korean drugmaker, D&D Pharmatech, claims that its products could eventually compete with industry leaders Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro....
Global News—Wegovy set to launch in Canada. What to know about the weight-loss drug. Wegovy can also be prescribed to patients who are significantly overweight and have at least one related medical condition such as high blood pressure and Type 2 diabetes.
dailym.ai—Women are reporting 'Ozempic breasts' while taking weight-loss drugs. Plastic surgeons say the rapid weight loss can also cause the breasts to sag. Ozempic users have opened up about experiencing shifts in breast size. READ MORE: Can weight loss drugs cause facial aging? Experts views
Kiplinger—Eli Lilly Stock Surges on Demand for Weight-Loss Drugs. Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.